Search - tctmd.com

Displaying 1 - 16 of 16

Sort: Relevancy | Date

News Daily News

CMR Picks Up Pericardial Inflammation in Student Athletes With COVID-19

Michael O'Riordan

November 06, 2020

News Daily News

Study Affirms Thrombotic Risk in COVID-19

Todd Neale

October 01, 2020

News Daily News

ABC-Bleeding Score Stratifies Risk in A-fib Patients on OAC and Aspirin

Todd Neale

September 21, 2020

News Daily News

High-Sensitivity Troponin Hones ASCVD Risk in Secondary Prevention

Michael O'Riordan

August 11, 2020

News Features

COVID-19’s Enduring Impact on the Heart? Some Clues and Predictions

Shelley Wood

July 20, 2020

News Daily News

Higher Risk of HF After ACS for Women Previously on Beta-blockers

Michael O'Riordan

July 16, 2020

News Daily News

THALES: Ticagrelor Plus Aspirin Cuts Repeat Events After Stroke, TIA

Todd Neale

July 16, 2020

News Daily News

Less MI, CV Death With Noninvasive Testing for Chest Pain: Observational Data

Michael O'Riordan

July 14, 2020

News Daily News

Heart, Kidneys, Brain, and More: COVID-19’s Wide-ranging Effects

Michael O'Riordan

July 13, 2020

News Daily News

Rivaroxaban May Yet Protect After a Hospital Stay: MARINER

Caitlin E. Cox

June 25, 2020

News Daily News

Most Stable Angina Patients Not Taking First-line Meds

Shelley Wood

June 18, 2020

News Daily News

Possible Antithrombotic and Anti-inflammatory Therapies for COVID-19

Michael O'Riordan

June 08, 2020

News Daily News

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

Michael O'Riordan

May 04, 2020

News Daily News

How COVID-19 Promotes Thrombosis, Posing Problems for Drug-Drug Interactions

Michael O'Riordan

April 22, 2020

News Daily News

Ticagrelor Hits Mark in Large Stroke Study: THALES Top-line Results

Michael O'Riordan

January 27, 2020

News Daily News

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

Michael O'Riordan

January 14, 2020

Advertisement

CMR Picks Up Pericardial Inflammation in Student Athletes With COVID-19

Study Affirms Thrombotic Risk in COVID-19

ABC-Bleeding Score Stratifies Risk in A-fib Patients on OAC and Aspirin

High-Sensitivity Troponin Hones ASCVD Risk in Secondary Prevention

COVID-19’s Enduring Impact on the Heart? Some Clues and Predictions

Higher Risk of HF After ACS for Women Previously on Beta-blockers

THALES: Ticagrelor Plus Aspirin Cuts Repeat Events After Stroke, TIA

Less MI, CV Death With Noninvasive Testing for Chest Pain: Observational Data

Heart, Kidneys, Brain, and More: COVID-19’s Wide-ranging Effects

Rivaroxaban May Yet Protect After a Hospital Stay: MARINER

Most Stable Angina Patients Not Taking First-line Meds

Possible Antithrombotic and Anti-inflammatory Therapies for COVID-19

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

How COVID-19 Promotes Thrombosis, Posing Problems for Drug-Drug Interactions

Ticagrelor Hits Mark in Large Stroke Study: THALES Top-line Results

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content